ALPS Advisors’s CytomX Therapeutics CTMX Stock Holding History

ALPS Advisors’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-107,100	Closed	-$402K	–	1206
2026 Q2	$402K	Buy	107,100 +1,280	+1%	+$4.89K	﹤0.01%	1046
2026 Q1	$497K	Buy	+105,820	New	+$537K	﹤0.01%	835
2022 Q2	–	Sell	-67,211	Closed	-$179K	–	1046
2022 Q1	$179K	Sell	67,211 -8,302	-11%	-$31.9K	﹤0.01%	809
2021 Q4	$327K	Sell	75,513 -4,340	-5%	-$25.4K	﹤0.01%	811
2021 Q3	$406K	Sell	79,853 -5,776	-7%	-$30.9K	﹤0.01%	538
2021 Q2	$542K	Buy	85,629 +2,000	+2%	+$15.6K	﹤0.01%	506
2021 Q1	$646K	Buy	83,629 +136	+0.2%	+$1.08K	0.01%	463
2020 Q4	$547K	Buy	+83,493	New	+$596K	0.01%	482
2020 Q2	–	Sell	-82,601	Closed	-$634K	–	791
2020 Q1	$634K	Sell	82,601 -9,632	-10%	-$67.2K	0.01%	402
2019 Q4	$766K	Buy	+92,233	New	+$622K	0.01%	423

Other funds holding CTMX

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Peak Financial Advisors Denver, Colorado $232M AUM 12.16% 1-Year Est. Return

Tema ETFs New York $2.69B AUM 42.96% 1-Year Est. Return

LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return

Robertson Stephens Wealth Management San Francisco, California $4.14B AUM 13.63% 1-Year Est. Return

ALPS Advisors's CTMX Position: Q3 2026 in Review

ALPS Advisors sold out of CytomX Therapeutics (CTMX) in Q3 2026, closing a stake of 107,100 shares — an estimated $402K sold.

ALPS Advisors first reported a position in CTMX in Q4 2019 and held it in 10 quarters. The position peaked at $766K in Q4 2019. 49 funds tracked by Wall St. Rank hold CTMX as of Q3 2026.

ALPS Advisors reported no remaining CytomX Therapeutics position as of Q3 2026 after selling out during the quarter.
ALPS Advisors sold 107,100 CytomX Therapeutics shares in Q3 2026, an estimated $402K.
ALPS Advisors first reported a position in CytomX Therapeutics in Q4 2019 and held it in 10 quarters.
ALPS Advisors's CytomX Therapeutics position peaked at $766K in Q4 2019.
49 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q3 2026.

Based on ALPS Advisors's 13F filing for Q3 2026, filed 3 Nov 2026.